Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 9/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.34 |
| ▸ | TBK1 | Q9UHD2 | 3/20 | 0.33 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 2/20 | 0.33 |
| ▸ | VEGFA | P15692 | 1/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.32 |
| ▸ | ATR | Q13535 | 1/20 | 0.32 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3051382 | 0.92 | NR1H2 (0.36) | NR1H2NR1H3TBK1CXCR4BRD4 | |
| SCHEMBL3037479 | 0.92 | NR1H2 (0.35) | NR1H2NR1H3TBK1CXCR4BRD4 | |
| SCHEMBL3034089 | 0.92 | NR1H2 (0.35) | NR1H2NR1H3TBK1CXCR4BRD4 | |
| SCHEMBL3051443 | 0.91 | TBK1 (0.36) | NR1H2NR1H3TBK1CXCR4BRD4 | |
| SCHEMBL3840174 | 0.91 | NR1H2 (0.37) | NR1H2NR1H3TBK1CXCR4BRD4 | |
| SCHEMBL3037182 | 0.90 | ACHE (0.37) | NR1H2TBK1SMN1; SMN2 | |
| SCHEMBL3048979 | 0.90 | NR1H2 (0.36) | NR1H2NR1H3TBK1BRD4CREBBP | |
| SCHEMBL5050607 | 0.89 | NR1H2 (0.37) | NR1H2NR1H3TBK1 | |
| SCHEMBL3051369 | 0.89 | NR1H2 (0.39) | NR1H2NR1H3BRD4CREBBP | |
| SCHEMBL3046133 | 0.89 | NR1H2 (0.34) | NR1H2NR1H3TBK1CXCR4BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745641-B2 | Nitrogen-containing heterocyclic compound | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-06-29 | — | — | US | disclosed |
| EP-2108642-A1 | JAK INHIBITOR | Kyowa Hakko Kirin Co., Ltd. (JP) | 2009-10-14 | — | — | EP | disclosed |
| US-20090054407-A1 | Nitrogen-containing heterocyclic compound | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-02-26 | — | — | US | disclosed |
| EP-1880993-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2008-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054407-A1 | Nitrogen-containing heterocyclic compound | NR4A1, NR5A2, PRMT8 | NR1H2 21/4885NR1H3 25/4885TBK1 3936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.